- Home
- products
- usa massachusetts
- testing services targeting to preclinical studies
Show results for
Refine by
Testing Services Targeting To Preclinical Studies Equipment Supplied In Usa Massachusetts
31 equipment items found
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso2 is a preclinical program targeting Crohn’s disease. It aims to develop Christensenella gut bacteria as a safe, efficient and groundbreaking oral biotherapy. YSOPIA has identified a lead candidate to relieve Crohn’s disease associated symptoms and slow down disease progression. Discover the articles we published in Scientific Reports: Relizani et al. 2022 and Kropp et al. 2021. ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled clinical trials evaluating both topical and intranasal routes of delivery of AOB with treatment durations ...
Manufactured by:Verax Biomedical, Incorporated based inMarlborough, MASSACHUSETTS (USA)
Verax is currently developing a version of its PGD test to address the risk of bacterial contamination in red blood cells. While the risk of red blood cell contamination is lower than the risk of platelet contamination, at 1:20,000, it is the second largest infectious risk for the nation’s blood supply and far exceeds the risk associated with transfusion-transmitted viruses such as HIV, ...
Manufactured by:Novo Nordisk A/S based inBagsværd, DENMARK
Our proprietary GalXC technology leverages a naturally occurring biologic process, ribonucleic acid interference, RNAi, to create therapies that silence disease-causing genes. This platform enables Dicerna to create molecules that can effectively interfere with the RNAi processes that lead to defective or misregulated proteins that cause disease. ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE707 is a preclinical discovery program for the prevention of infection and colonization recurrence of several multi-drug resistant organisms (MDROs) including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE), which are some of the most common hospital-acquired ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Selecta’s first ImmTORTM + gene therapy candidate MMA-101 for methylmalonic acidemia (MMA) is expected to enter clinical trials the end of 2021. MMA is a rare metabolic disease that may lead to metabolic acidosis and hyperammonemia and is associated with long-term complications including feeding problems, developmental delay, intellectual disability, and chronic kidney ...
by:Aegle Therapeutics based inWoburn, MASSACHUSETTS (USA)
Advancement of extracellular vesicle therapy to the patient has been hampered by an inability to isolate extracellular vesicles in useful quantities while preserving their structural and functional integrity. EVs derived from MSCs enjoy the same immunosuppressant characteristics of their parent cells. However, when EVs are processed incorrectly, they can trigger an adverse inflammation response ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso3 is a preclinical drug development program aimed at treating asthma. Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. We have achieved the formulation feasibility ...
Manufactured by:Kuros Biosciences A.G. based inSchlieren, SWITZERLAND
MagnetOs isn’t like other bone grafts. It grows bone even in soft tissue thanks to our unique NeedleGrip™ surface technology which provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages).*†6,7 This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft.*8-10 ...
by:OSSIO Inc based inWoburn, MASSACHUSETTS (USA)
OSSIOfiber® Cannulated and Solid-Core Fixation Nails allow surgeons to offer patients a strong and biointegrative solution for a wide range of surgical techniques. Comprised of OSSIOfiber® Intelligent Bone Regeneration Technology, Fully integrates into native anatomy without adverse inflammation,, as proven in pre-clinical studies, Rivals performance of metal headless cannulated ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg dose in a lymphoma study and with a maximum ...
Manufactured by:Kalaris based inWaltham, MASSACHUSETTS (USA)
Kalaris Therapeutics is focused on developing innovative treatments for retinal diseases, aiming to reduce the burden of frequent clinical visits for patients with retinal neovascular and exudative conditions. Their lead product, TH103, is a fully humanized, recombinant fusion protein designed for intravitreal delivery as an anti-VEGF agent. TH103 functions as a soluble decoy receptor, ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, which is advantageous when bystander cells are cancerous but toxic if the cytotoxic drug is able to enter adjacent healthy cells. The DolaLock payload ...
by:Harvard Apparatus Regenerative Technology, Inc. formely known as Biostage, Inc. based inHolliston, MASSACHUSETTS (USA)
Following extensive research and development, Biostage has evolved its technology to optimize the interaction of mesenchymal stem cells seeded on a biocompatible scaffold. Preclinical studies suggest that, once implanted, the scaffold seeded with the patient’s own cells signals the stem cell niche to guide the regeneration of a biological ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
The first patient was dosed with our investigational genome editing treatment for transthyretin (ATTR) amyloidosis in November 2020. Our modular approach enables us to optimize the power and versatility of the CRISPR/Cas9 technology and, importantly, allows us to rapidly develop therapeutics for numerous diseases that currently have limited treatment ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures. In preclinical studies, we have observed that the removal of CD33 ...
Manufactured by:Galatea Surgical, Inc. based inLexington, MASSACHUSETTS (USA)
A lightweight, low-profile P4HB scaffold, designed for anatomical compliance, to provide predictable, restorative strength. Soft Meets Strength: In preclinical studies, GalaFLEX LITE showed rapid tissue regeneration, resulting in a new tissue plane twice the strength of the native tissue. GalaFLEX LITE retains strength, supporting and reinforcing the surgical repair for a ...
by:OSSIO Inc based inWoburn, MASSACHUSETTS (USA)
Bio-Integrative OSSIOfiber® Hammertoe Fixation System. Innovation and Convenience Delivered In One Package. The combination of the implant plus disposable instrumentation provides easy insertion and secure fixation for proximal interphalangeal (PIP) fusion procedures while utilizing existing surgical ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
FOTIVDA (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1,2 AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA in March 2021 for the treatment of adult patients ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Evaluate drug candidate toxicity at clinically relevant concentrations in a co-culture human kidney model. Predicting drug-induced kidney toxicity and drug-drug interactions continues to be a challenge due to a reliance on immortalized cell line culture or animal models that do not translate to human response. The co-culture Emulate Kidney-Chip combines primary human cells in a dynamic ...